SPECIAL FEATURES

6395 Assessing Iron Overload: Are We There Yet? Paul C. Kruger, Michael F. Leahy, and John K. Olynyk See article p. 6460

6398 Improving Publication Rates of Biomarker Results from Cancer Trials Robert Iannone See article p. 6478

Molecular Pathways

6400 Molecular Pathways: Understanding the Role of Rad52 in Homologous Recombination for Therapeutic Advancement Benjamin H. Lok and Simon N. Powell

Review

6407 p53 Arg72Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis Steven Habbous, Vincent Pang, Lawson Eng, Wei Xu, Goldie Kurtz, Fei-Fei Liu, Helen Mackay, Eitan Amir, and Geoffrey Liu

HUMAN CANCER BIOLOGY

6416 Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9 Mei-Hsuan Lu, Chao-Cheng Huang, Mei-Ren Pan, Hong-Hwa Chen, and Wen-Chun Hung

6426 Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping Julia D. Wulfkuhle, Daniela Berg, Claudia Wolff, Rupert Langer, Kai Tran, Julie Illi, Virginia Espina, Marielena Pierobon, Jianghong Deng, Angela DeMichele, Axel Walch, Holger Bronger, Ingrid Becker, Christine Waldhor, Heinz Höfler, Laura Eserman on behalf of the I-SPY 1 TRIAL Investigators, Lance A. Lioetta, Karl-Friedrich Becker, and Emanuel F. Petricoin III

CANCER THERAPY: PRECLINICAL

6436 Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies Koji Tamada, Degui Geng, Yukimi Sakoda, Navneeta Bansal, Ratika Srivastava, Zhaoyang Li, and Eduardo Davila

6446 Vaccination with Irradiated Tumor Cells Pulsed with an Adjuvant That Stimulates NKT Cells Is an Effective Treatment for Glioma Martin K. Hunn, Kathryn J. Farrand, Kate W.R. Broadley, Robert Weinkove, Peter Fergusson, Rose J. Miller, Cameron S. Field, Troels Petersen, Melanie J. McConnell, and Ian F. Hermans

IMAGING, DIAGNOSIS, PROGNOSIS

6460 MRI-Based Liver Iron Content Predicts for Nonrelapse Mortality in MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation Martin Wermke, Anne Schmidt, Jan Moritz Middeke, Katja Sockel, Malte von Bonin, Claudia Schönfeldt, Sabine Mair, Verena Ploedek, Michael Laniado, Günter Weiss, Johannes Schetelig, Gerhard Ehninger, Igor Theurl, Martin Bornhauser, and Uwe Platzbecker See commentary p. 6395

6469 Combretastatin A-4 Phosphate Affects Tumor Vessel Volume and Size Distribution as Assessed Using MRI-Based Vessel Size Imaging Thomas Nielsen, Lise Bentzen, Michael Pedersen, Trine Tramm, Paul F.J.W. Rijken, Johan Bussink, Michael R. Horsman, and Leif Østergaard
CANCER THERAPY: CLINICAL

6478 Publication and Reporting Conduct for Pharmacodynamic Analyses of Tumor Tissue in Early-Phase Oncology Trials
Georgina A. Freeman and Jonathan Kimmelman
See commentary p. 6398

6485 Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides
Paola Filipazzi, Lorenzo Pilla, Luigi Mariani, Roberto Patuzzo, Chiara Castelli, Chiara Carnisacchi, Andrea Maurichi, Agata Cova, Gianluigi Rigamonti, Felicetta Giardino, Annabella Di Florio, Marco Ascoli, Paola Frati, Gloria Soven, Paola Squarcina, Michele Maio, Riccardo Danielli, Vanna Chiarion-Sileni, Antonello Villa, Claudia Lombardo, Gabrina Tragni, Mario Santinami, Giorgio Parmiani, and Licia Rivoltini

6497 Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6509 A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
Stanley B. Kaye, Louis Fehrenbacher, Robert Holloway, Amnon Amit, Beth Karlan, Brian Slomovitz, Paul Sabbatini, Ling Fu, Robert L. Yau, Il Sung Chang, and Josina C. Reddy

6519 Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity
Yunfeng Cui, Jacqueline A. Brosnan, Amanda L. Blackford, Sarojit Sur, Ralph H. Hruban, Kenneth W. Kinzler, Bert Vogelstein, Anirban Maitra, Luis A. Diaz Jr., Christine A. Iacobuzio-Donahue, and James R. Eshleman

6531 Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

6542 Acknowledgment to Reviewers

ABOUT THE COVER

Expression of GFP-tagged PROX1 in colon cancer cells reduced E-cadherin and induced epithelial–mesenchymal transition. We found that PROX1 activated miR-9 expression to attenuate E-cadherin protein posttranslationally. Results of this study provide a molecular basis by which PROX1 promotes tumorigenesis of colon cancer. For details, see the article by Lu and colleagues on page 6416 of this issue.